Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Intangibles (2023 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Intangibles for 3 consecutive years, with $93.9 million as the latest value for Q4 2025.

  • Quarterly Intangibles fell 37.65% to $93.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $93.9 million through Dec 2025, down 37.65% year-over-year, with the annual reading at $93.9 million for FY2025, 37.65% down from the prior year.
  • Intangibles for Q4 2025 was $93.9 million at Cartesian Therapeutics, down from $150.6 million in the prior quarter.
  • The five-year high for Intangibles was $150.6 million in Q4 2023, with the low at $93.9 million in Q4 2025.
  • Average Intangibles over 3 years is $144.3 million, with a median of $150.6 million recorded in 2023.
  • The sharpest move saw Intangibles changed 0.0% in 2024, then plummeted 37.65% in 2025.
  • Over 3 years, Intangibles stood at $150.6 million in 2023, then changed by 0.0% to $150.6 million in 2024, then tumbled by 37.65% to $93.9 million in 2025.
  • According to Business Quant data, Intangibles over the past three periods came in at $93.9 million, $150.6 million, and $150.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.